<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04244825</url>
  </required_header>
  <id_info>
    <org_study_id>B-2660-203</org_study_id>
    <nct_id>NCT04244825</nct_id>
  </id_info>
  <brief_title>Safety, Pharmacodynamics, and Pharmacokinetics of Orally Administered BLD-2660 in Subjects With IPF</brief_title>
  <official_title>A Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate Pharmacodynamics, Pharmacokinetics, and Safety of BLD-2660 Administered Orally in Subjects With Idiopathic Pulmonary Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Blade Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Blade Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate Pharmacodynamics,&#xD;
      Pharmacokinetics, and Safety of BLD-2660 Administered Orally in Subjects with Idiopathic&#xD;
      Pulmonary Fibrosis&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2a, double-blind, placebo-controlled, multicentre, adaptive design study of&#xD;
      BLD-2660 in subjects with IPF. The study will include a Screening period, a Treatment period,&#xD;
      and a Follow-up period. Data on PK, PD, and biomarker activity will be observed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Withdrawn due to concerns for patient safety during COVID-19 crisis&#xD;
  </why_stopped>
  <start_date type="Actual">December 15, 2019</start_date>
  <completion_date type="Actual">November 5, 2020</completion_date>
  <primary_completion_date type="Actual">September 14, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Observed changes in ILK from baseline</measure>
    <time_frame>58 days</time_frame>
    <description>Change in RLU of BAL fluid analyzed by ILK-targeting ELISA assay. Analysis of difference in RLU correlates to change in cellular ILK from baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Observed changes in spectrin from baseline</measure>
    <time_frame>58 days</time_frame>
    <description>Change in RLU of BAL fluid analyzed by spectrin-targeting ELISA assay. Analysis of difference in RLU correlates to change in cellular spectrin from baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Observed changes in ezrin from baseline</measure>
    <time_frame>58 days</time_frame>
    <description>Change in RLU of BAL fluid analyzed by ezrin-targeting ELISA assay. Analysis of difference in RLU correlates to change in cellular ezrin from baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Observed changes in S100A9 from baseline</measure>
    <time_frame>58 days</time_frame>
    <description>Change in RLU of BAL fluid analyzed by S100A9-targeting ELISA assay. Analysis of difference in RLU correlates to change in cellular S100A9 from baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the drug concentration-time curve from time zero to the last measurable concentration (AUC0-last)</measure>
    <time_frame>58 days</time_frame>
    <description>Measured by plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC from time 0 to infinity (AUC0-inf)</measure>
    <time_frame>58 days</time_frame>
    <description>Measured by plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed drug concentration (Cmax)</measure>
    <time_frame>58 days</time_frame>
    <description>Measured by plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of the maximum drug concentration (Tmax)</measure>
    <time_frame>58 days</time_frame>
    <description>Measured by plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events as assessed by PI and SMC</measure>
    <time_frame>58 days</time_frame>
    <description>AEs will be assessed by determining the incidence, severity, and dose relationship of adverse events.</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>Cohort 1a BLD-2660</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>900 mg (6 x 150 mg capsules) BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1b BLD-2660</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>900 mg (6 x 150 mg capsules) BID (Optional)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 BLD-2660</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>600 mg (4 x 150 mg capsules) BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 BLD-2660</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 mg (2 x 150 mg capsules) BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1a Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>900 mg (6 x 150 mg capsules) BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1b Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>900 mg (6 x 150 mg capsules) BID (Optional)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>600 mg (4 x 150 mg capsules) BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>300 mg (2 x 150 mg capsules) BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BLD-2660</intervention_name>
    <description>BLD-2660 - 150 mg capsules '00' size (PO) BID</description>
    <arm_group_label>Cohort 1a BLD-2660</arm_group_label>
    <arm_group_label>Cohort 1b BLD-2660</arm_group_label>
    <arm_group_label>Cohort 2 BLD-2660</arm_group_label>
    <arm_group_label>Cohort 3 BLD-2660</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Control: Placebo</intervention_name>
    <description>Placebo - 150 mg capsules '00' size (PO) BID</description>
    <arm_group_label>Cohort 1a Placebo</arm_group_label>
    <arm_group_label>Cohort 1b Placebo</arm_group_label>
    <arm_group_label>Cohort 2 Placebo</arm_group_label>
    <arm_group_label>Cohort 3 Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        To be eligible for inclusion into this study, each subject must fulfill the following&#xD;
        inclusion criteria within 20 days prior to Randomization on Day 1:&#xD;
&#xD;
        Age and Gender&#xD;
&#xD;
          1. Male subjects 45 years of age and over, or female subjects 50 years of age and over,&#xD;
             at the time of signing the informed consent.&#xD;
&#xD;
             Diagnosis and disease characteristics&#xD;
&#xD;
          2. Subjects with diagnosis of IPF as defined by the American Thoracic Society/European&#xD;
             Respiratory Society International Multidisciplinary Consensus Classification of&#xD;
             Idiopathic Interstitial Pneumonia.&#xD;
&#xD;
          3. Forced vital capacity (FVC) &gt;45% predicted and diffusing capacity of the lung for&#xD;
             carbon monoxide (DLCO) &gt;30% predicted.&#xD;
&#xD;
          4. Alanine aminotransferase (ALT) within normal limit (WNL).&#xD;
&#xD;
          5. Aspartate aminotransferase (AST) and alkaline phosphatase (ALP) ≤1.2× upper limit of&#xD;
             normal (ULN).&#xD;
&#xD;
          6. Total bilirubin ≤ULN (isolated bilirubinemia ≤2× ULN is acceptable if direct bilirubin&#xD;
             to total bilirubin ratio &lt;0.35).&#xD;
&#xD;
          7. Body mass index (BMI) up to 35 kg/m2 inclusive. Reproductive Considerations&#xD;
             Contraception use by men or women should be consistent with local regulations&#xD;
             regarding the methods of contraception for those participating in clinical studies.&#xD;
&#xD;
          8. All subjects (male or female) who are of childbearing potential must agree to use&#xD;
             highly effective contraception during the study.&#xD;
&#xD;
          9. Male subjects and female partners of male subjects must continue to use highly&#xD;
             effective contraception for 90 days after the last dose of study drug (see Medicines&#xD;
             and Healthcare products Regulatory Agency, 2019 for further guidance regarding highly&#xD;
             effective contraception). Male subjects must agree not to donate sperm for 90 days&#xD;
             after last dose of study drug.&#xD;
&#xD;
         10. Female subjects and male partners of female subjects must continue to use highly&#xD;
             effective contraception for 60 days after the last dose of study drug. Female subjects&#xD;
             should not donate oocytes during this time.&#xD;
&#xD;
         11. Female subjects of childbearing potential must have a negative serum pregnancy test at&#xD;
             Screening and a negative urine pregnancy test on Day (-1). Women of childbearing&#xD;
             potential (WOCBP) must agree to undergo pregnancy testing at regular intervals&#xD;
             throughout the study.&#xD;
&#xD;
         12. Female subjects not of childbearing potential as defined by being postmenopausal (with&#xD;
             cessation of regular menstrual periods for at least 1 year), confirmed by follicle&#xD;
             stimulating hormone (FSH) level, or be surgically sterile.&#xD;
&#xD;
             Informed Consent&#xD;
&#xD;
         13. Subjects must provide signed informed consent prior to study entry and have the&#xD;
             ability and willingness to attend and comply with the necessary visits at the study&#xD;
             site.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        To be eligible for inclusion into this study, each subject must violate none of the&#xD;
        following exclusion criteria within 20 days prior to Randomisation on Day 1.&#xD;
&#xD;
        Medical Conditions&#xD;
&#xD;
          1. Recent (less than 6 weeks) significant wound (in the opinion of the Investigator), or&#xD;
             presence of an ongoing non-healing skin wound or ulcer.&#xD;
&#xD;
          2. Presence of any underlying physical or psychological medical condition that, in the&#xD;
             opinion of the Investigator, would make it unlikely that the subject will complete the&#xD;
             study per protocol.&#xD;
&#xD;
          3. Active infection (diagnosed or suspected) or history of recurrent infections,&#xD;
             including but is not limited to, bronchitis, pneumonia, sinusitis, urinary tract&#xD;
             infection, cellulitis or chronic ongoing infectious disease within 4 weeks prior to&#xD;
             first dose of study drug. Note: Rescreening will be permitted after 28 days if an&#xD;
             infection leads to screening failure.&#xD;
&#xD;
          4. Active malignancy and/or history of malignancy in the past 5 years, except for&#xD;
             non-melanoma skin cancer, carcinoma in situ of the breast that has been successfully&#xD;
             treated, carcinoma in situ of the cervix that has been successfully treated, early&#xD;
             stage, untreated prostate cancer, or prostate cancer with completion of treatment &gt;2&#xD;
             years prior to Screening.&#xD;
&#xD;
          5. Extensive chronic obstructive pulmonary disease (where extent of emphysema &gt;extent of&#xD;
             fibrosis on computerised tomography (CT) scan or FEV1: FVC ratio &lt;0.65).&#xD;
&#xD;
          6. Other explanation for lung fibrosis, including but not limited to radiation,&#xD;
             sarcoidosis, bronchiolitis obliterans organizing pneumonia, collagen vascular disease,&#xD;
             hypersensitivity pneumonitis, etc.&#xD;
&#xD;
          7. IPF exacerbation within last 60 days.&#xD;
&#xD;
          8. A history or current evidence of any medical condition, therapy, or laboratory&#xD;
             abnormality that might confound the results of the study, interfere with the subjects'&#xD;
             participation for the full duration of the study, or is not in the best interest of&#xD;
             the subjects to participate, in the opinion of the Investigator.&#xD;
&#xD;
             Diagnostic Assessments&#xD;
&#xD;
          9. Positivity for Human Immunodeficiency Virus (HIV) antibody (HIV-1 and/or HIV-2) and/or&#xD;
             HIV-1 p24 antigen.&#xD;
&#xD;
         10. Positivity for Hepatitis C virus antibody (HCV Ab or anti-HCV) and/or Hepatitis B&#xD;
             surface antigen (HBsAg).&#xD;
&#xD;
         11. Absolute neutrophil count &lt;1700/µL.&#xD;
&#xD;
         12. Significant hypoxia, requiring &gt;2 L/min oxygen to maintain a resting oxygen saturation&#xD;
             &gt;89%.&#xD;
&#xD;
         13. Poor exercise tolerance.&#xD;
&#xD;
         14. Serum troponin I level &gt;ULN.&#xD;
&#xD;
             Prior/Concomitant Therapy&#xD;
&#xD;
         15. Use of anticoagulants that prolong Prothrombin time (PT)/International normalised&#xD;
             ratio (INR).&#xD;
&#xD;
         16. Use of anticoagulants within 2 days of Day (-1) (bronchoscopy). Note: The subjects who&#xD;
             cannot discontinue the anticoagulants within 2 days of Day (-1) bronchoscopy will be&#xD;
             excluded.&#xD;
&#xD;
         17. Treatment with any anti-fibrotic therapy (pirfenidone or nintedanib) within 30 days of&#xD;
             Screening.&#xD;
&#xD;
         18. Immunosuppressive therapy within 3 months prior to first dose of study drug (unless&#xD;
             for non-IPF indication).&#xD;
&#xD;
         19. Use of oral steroids &gt;10 mg/day (or prednisolone equivalent). Note: If the subject is&#xD;
             on steroid dose equivalent to 10 mg/day prednisone or more, the Investigator may&#xD;
             decide if the tapering down to the dose of 10 mg/day prednisone is possible and safe.&#xD;
&#xD;
         20. Start of new biologic or change in biologic dose within 24 weeks prior to Day 1.&#xD;
&#xD;
         21. Cyclophosphamide within 6 months prior to the first dose of study drug (unless for&#xD;
             other indication).&#xD;
&#xD;
             Prior/Concurrent Clinical Study Experience&#xD;
&#xD;
         22. Administration of another investigational product, investigational device, or approved&#xD;
             therapy for investigational use within 30 days prior to the first study drug&#xD;
             administration, or five half-lives, whichever is longer.&#xD;
&#xD;
             Other Exclusions&#xD;
&#xD;
         23. Blood donation or significant blood loss within 60 days prior to the first study drug&#xD;
             administration.&#xD;
&#xD;
         24. Plasma donation within 7 days prior to the first study drug administration.&#xD;
&#xD;
         25. Female subjects who are pregnant or breastfeeding.&#xD;
&#xD;
         26. History or presence of alcohol or drug abuse (including recreational marijuana use)&#xD;
             within the 2 year prior to the first study drug administration, and unwillingness to&#xD;
             be totally abstinent during the dosing period.&#xD;
&#xD;
         27. Active smoker, smoking history or vaping within 4 weeks prior to the first dose of&#xD;
             study drug. Subjects only using Nicotine replacement therapy (NRT) may be allowed per&#xD;
             discretion of the Investigator.&#xD;
&#xD;
         28. Subjects with an allergy to BLD-2660 or inactive components of BLD-2660.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Blade Research Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 3, 2020</study_first_submitted>
  <study_first_submitted_qc>January 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 28, 2020</study_first_posted>
  <last_update_submitted>March 2, 2021</last_update_submitted>
  <last_update_submitted_qc>March 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

